{
  "metadata": {
    "source": "ClinicalTrials.gov",
    "update_date": "2025-06-26T00:39:19.730524",
    "total_trials": 127,
    "active_trials": 44
  },
  "trials": [
    {
      "NCTId": "NCT03316560",
      "BriefTitle": "Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations",
      "Phase": "PHASE1, PHASE2",
      "StartDate": "2018-04-16",
      "CompletionDate": "2025-03-01",
      "Status": "ACTIVE_NOT_RECRUITING",
      "SponsorName": "Beacon Therapeutics",
      "is_gene_therapy": 1,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT06455826",
      "BriefTitle": "MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)",
      "Phase": "PHASE1",
      "StartDate": "2024-06-13",
      "CompletionDate": "2025-11-01",
      "Status": "RECRUITING",
      "SponsorName": "PYC Therapeutics",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT02609165",
      "BriefTitle": "Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular Edema",
      "Phase": "PHASE2",
      "StartDate": "",
      "CompletionDate": "2017-02-01",
      "Status": "COMPLETED",
      "SponsorName": "Ospedale San Raffaele",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT03780257",
      "BriefTitle": "Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene",
      "Phase": "PHASE1, PHASE2",
      "StartDate": "2019-03-06",
      "CompletionDate": "",
      "Status": "COMPLETED",
      "SponsorName": "ProQR Therapeutics",
      "is_gene_therapy": 1,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT05712148",
      "BriefTitle": "Spheroidal Mesenchymal Stem Cells in Retinitis Pigmentosa",
      "Phase": "PHASE1, PHASE2",
      "StartDate": "2019-10-11",
      "CompletionDate": "",
      "Status": "COMPLETED",
      "SponsorName": "Acibadem University",
      "is_gene_therapy": 0,
      "is_cell_therapy": 1
    },
    {
      "NCTId": "NCT03328130",
      "BriefTitle": "Safety and Efficacy Study in Patients With Retinitis Pigmentosa Due to Mutations in PDE6B Gene",
      "Phase": "PHASE1, PHASE2",
      "StartDate": "2017-11-06",
      "CompletionDate": "2029-12-01",
      "Status": "RECRUITING",
      "SponsorName": "eyeDNA Therapeutics",
      "is_gene_therapy": 1,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT01531348",
      "BriefTitle": "Intravitreal Injection of MSCs in Retinitis Pigmentosa",
      "Phase": "PHASE1",
      "StartDate": "",
      "CompletionDate": "2020-07-01",
      "Status": "COMPLETED",
      "SponsorName": "Mahidol University",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT04123626",
      "BriefTitle": "A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene",
      "Phase": "PHASE1, PHASE2",
      "StartDate": "2019-10-07",
      "CompletionDate": "",
      "Status": "ACTIVE_NOT_RECRUITING",
      "SponsorName": "ProQR Therapeutics",
      "is_gene_therapy": 1,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT02110225",
      "BriefTitle": "A Dose Ranging Study to Evaluate the Safety and Potential Efficacy of rhNGF in Patients With Retinitis Pigmentosa (RP)",
      "Phase": "PHASE1, PHASE2",
      "StartDate": "",
      "CompletionDate": "2015-11-01",
      "Status": "COMPLETED",
      "SponsorName": "Dompé Farmaceutici S.p.A",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT05413148",
      "BriefTitle": "The Effect of Stem Cells and Stem Cell Exosomes on Visual Functions in Patients With Retinitis Pigmentosa",
      "Phase": "PHASE2, PHASE3",
      "StartDate": "2022-08-05",
      "CompletionDate": "",
      "Status": "UNKNOWN",
      "SponsorName": "TC Erciyes University",
      "is_gene_therapy": 0,
      "is_cell_therapy": 1
    },
    {
      "NCTId": "NCT02280135",
      "BriefTitle": "Clinical Trial of Intravitreal Injection of Autologous Bone Marrow Stem Cells in Patients With Retinitis Pigmentosa",
      "Phase": "PHASE1",
      "StartDate": "",
      "CompletionDate": "2017-03-01",
      "Status": "COMPLETED",
      "SponsorName": "Red de Terapia Celular",
      "is_gene_therapy": 0,
      "is_cell_therapy": 1
    },
    {
      "NCTId": "NCT06852963",
      "BriefTitle": "A Study of Two Doses of VP-001 Administered Intravitreally in Participants with Confirmed PRPF31 Mutation-Associated Retinal Dystrophy Previously Treated with VP001",
      "Phase": "PHASE1, PHASE2",
      "StartDate": "2025-06-01",
      "CompletionDate": "",
      "Status": "NOT_YET_RECRUITING",
      "SponsorName": "PYC Therapeutics",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT04356716",
      "BriefTitle": "Sildenafil for Treatment of Choroidal Ischemia",
      "Phase": "PHASE2",
      "StartDate": "2014-11-11",
      "CompletionDate": "2024-12-01",
      "Status": "ACTIVE_NOT_RECRUITING",
      "SponsorName": "Columbia University",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT05194124",
      "BriefTitle": "Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway",
      "Phase": "PHASE3",
      "StartDate": "2021-12-21",
      "CompletionDate": "",
      "Status": "COMPLETED",
      "SponsorName": "Rhythm Pharmaceuticals, Inc.",
      "is_gene_therapy": 1,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT04864496",
      "BriefTitle": "Effects of Treatment With N- Acetylcysteine on Visual Outcomes in Patients With Retinitis Pigmentosa",
      "Phase": "PHASE2",
      "StartDate": "2021-04-17",
      "CompletionDate": "",
      "Status": "UNKNOWN",
      "SponsorName": "Shahid Beheshti University of Medical Sciences",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT00000116",
      "BriefTitle": "Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A",
      "Phase": "PHASE3",
      "StartDate": "",
      "CompletionDate": "2002-09-01",
      "Status": "COMPLETED",
      "SponsorName": "Carol Weigel DiFranco",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT05158296",
      "BriefTitle": "Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)",
      "Phase": "PHASE2, PHASE3",
      "StartDate": "2021-12-08",
      "CompletionDate": "",
      "Status": "TERMINATED",
      "SponsorName": "Laboratoires Thea",
      "is_gene_therapy": 1,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT00661479",
      "BriefTitle": "An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant in Patients With Retinitis Pigmentosa",
      "Phase": "PHASE1, PHASE2",
      "StartDate": "",
      "CompletionDate": "2010-05-01",
      "Status": "COMPLETED",
      "SponsorName": "Allergan",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT03999021",
      "BriefTitle": "FIGHT-RP 1 Extension Study",
      "Phase": "PHASE1",
      "StartDate": "2019-06-24",
      "CompletionDate": "2027-06-01",
      "Status": "ACTIVE_NOT_RECRUITING",
      "SponsorName": "Johns Hopkins University",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT03063021",
      "BriefTitle": "The FIGHT-RP1 Study",
      "Phase": "PHASE1",
      "StartDate": "2017-02-15",
      "CompletionDate": "",
      "Status": "COMPLETED",
      "SponsorName": "Johns Hopkins University",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT03184584",
      "BriefTitle": "Open-Label Rollover Study of PBI 4050 in Subjects With Alström Syndrome",
      "Phase": "PHASE2, PHASE3",
      "StartDate": "2017-10-09",
      "CompletionDate": "",
      "Status": "TERMINATED",
      "SponsorName": "Liminal BioSciences Ltd.",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT05085964",
      "BriefTitle": "An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa",
      "Phase": "PHASE2",
      "StartDate": "2021-09-16",
      "CompletionDate": "",
      "Status": "TERMINATED",
      "SponsorName": "Laboratoires Thea",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT06627179",
      "BriefTitle": "Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene",
      "Phase": "PHASE2",
      "StartDate": "2024-12-11",
      "CompletionDate": "2027-12-01",
      "Status": "RECRUITING",
      "SponsorName": "Laboratoires Thea",
      "is_gene_therapy": 1,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT05392179",
      "BriefTitle": "A Study in Subjects With Retinitis Pigmentosa",
      "Phase": "PHASE2",
      "StartDate": "2022-07-14",
      "CompletionDate": "",
      "Status": "COMPLETED",
      "SponsorName": "Aldeyra Therapeutics, Inc.",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT06242379",
      "BriefTitle": "Safety and Efficacy of Stem Cell Small Extracellular Vesicles in Patients With Retinitis Pigmentosa",
      "Phase": "PHASE1, PHASE2",
      "StartDate": "2024-05-23",
      "CompletionDate": "",
      "Status": "RECRUITING",
      "SponsorName": "Mahidol University",
      "is_gene_therapy": 0,
      "is_cell_therapy": 1
    },
    {
      "NCTId": "NCT02140164",
      "BriefTitle": "Study of Oral Minocycline in Treating Bilateral Cystoid Macular Edema Associated With Retinitis Pigmentosa",
      "Phase": "PHASE1, PHASE2",
      "StartDate": "",
      "CompletionDate": "2016-06-01",
      "Status": "COMPLETED",
      "SponsorName": "National Eye Institute (NEI)",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT03772938",
      "BriefTitle": "Stem Cells Therapy in Degenerative Diseases of the Retina",
      "Phase": "PHASE1",
      "StartDate": "2018-12-13",
      "CompletionDate": "",
      "Status": "UNKNOWN",
      "SponsorName": "Pomeranian Medical University Szczecin",
      "is_gene_therapy": 1,
      "is_cell_therapy": 1
    },
    {
      "NCTId": "NCT01680510",
      "BriefTitle": "The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella Bardawil",
      "Phase": "PHASE1, PHASE2",
      "StartDate": "2012-09-01",
      "CompletionDate": "",
      "Status": "ACTIVE_NOT_RECRUITING",
      "SponsorName": "Sheba Medical Center",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT05874310",
      "BriefTitle": "Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa",
      "Phase": "EARLY_PHASE1",
      "StartDate": "2023-02-01",
      "CompletionDate": "",
      "Status": "RECRUITING",
      "SponsorName": "Frontera Therapeutics",
      "is_gene_therapy": 1,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT06292650",
      "BriefTitle": "Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa Patients",
      "Phase": "EARLY_PHASE1",
      "StartDate": "2024-02-25",
      "CompletionDate": "",
      "Status": "RECRUITING",
      "SponsorName": "Zhongmou Therapeutics",
      "is_gene_therapy": 1,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT00065455",
      "BriefTitle": "Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa",
      "Phase": "PHASE1",
      "StartDate": "2003-07-17",
      "CompletionDate": "",
      "Status": "COMPLETED",
      "SponsorName": "National Eye Institute (NEI)",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT04611503",
      "BriefTitle": "PDE6A Gene Therapy for Retinitis Pigmentosa",
      "Phase": "PHASE1, PHASE2",
      "StartDate": "2019-09-24",
      "CompletionDate": "2027-07-01",
      "Status": "ACTIVE_NOT_RECRUITING",
      "SponsorName": "STZ eyetrial",
      "is_gene_therapy": 1,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT06492850",
      "BriefTitle": "Gene Therapy for RPGR Gene Mutation-associated X-linked Retinitis Pigmentosa",
      "Phase": "PHASE1, PHASE2",
      "StartDate": "2024-04-01",
      "CompletionDate": "",
      "Status": "RECRUITING",
      "SponsorName": "Frontera Therapeutics",
      "is_gene_therapy": 1,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT02320812",
      "BriefTitle": "Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Retinitis Pigmentosa",
      "Phase": "PHASE1, PHASE2",
      "StartDate": "",
      "CompletionDate": "",
      "Status": "COMPLETED",
      "SponsorName": "jCyte, Inc",
      "is_gene_therapy": 0,
      "is_cell_therapy": 1
    },
    {
      "NCTId": "NCT00000114",
      "BriefTitle": "Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa",
      "Phase": "PHASE3",
      "StartDate": "",
      "CompletionDate": "1987-06-01",
      "Status": "COMPLETED",
      "SponsorName": "National Eye Institute (NEI)",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT04763369",
      "BriefTitle": "Investigation of Therapeutic Efficacy and Safety of UMSCs for the Management of Retinitis Pigmentosa (RP)",
      "Phase": "PHASE2",
      "StartDate": "",
      "CompletionDate": "2022-06-01",
      "Status": "UNKNOWN",
      "SponsorName": "Jinnah Burn and Reconstructive Surgery Centre, Lahore",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT06936787",
      "BriefTitle": "An Open-label, Dose-ascending Study of IGT001 for Retinitis Pigmentosa",
      "Phase": "PHASE1",
      "StartDate": "2025-04-20",
      "CompletionDate": "",
      "Status": "RECRUITING",
      "SponsorName": "Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT02556736",
      "BriefTitle": "RST-001 Phase I/II Trial for Advanced Retinitis Pigmentosa",
      "Phase": "PHASE1, PHASE2",
      "StartDate": "2015-12-14",
      "CompletionDate": "",
      "Status": "COMPLETED",
      "SponsorName": "AbbVie",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT02464436",
      "BriefTitle": "Safety and Tolerability of hRPC in Retinitis Pigmentosa",
      "Phase": "PHASE1, PHASE2",
      "StartDate": "",
      "CompletionDate": "2023-12-01",
      "Status": "ACTIVE_NOT_RECRUITING",
      "SponsorName": "ReNeuron Limited",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT01914913",
      "BriefTitle": "Clinical Study to Evaluate Safety and Efficacy of BMMNC in Retinitis Pigmentosa",
      "Phase": "PHASE1, PHASE2",
      "StartDate": "",
      "CompletionDate": "2016-11-01",
      "Status": "UNKNOWN",
      "SponsorName": "Chaitanya Hospital, Pune",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT01461213",
      "BriefTitle": "Gene Therapy for Blindness Caused by Choroideremia",
      "Phase": "PHASE1, PHASE2",
      "StartDate": "",
      "CompletionDate": "2017-10-01",
      "Status": "COMPLETED",
      "SponsorName": "University of Oxford",
      "is_gene_therapy": 1,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT04794101",
      "BriefTitle": "Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene",
      "Phase": "PHASE3",
      "StartDate": "2020-12-04",
      "CompletionDate": "",
      "Status": "ACTIVE_NOT_RECRUITING",
      "SponsorName": "Janssen Research & Development, LLC",
      "is_gene_therapy": 1,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT05800301",
      "BriefTitle": "Management of Retinitis Pigmentosa Via Combination of Wharton's Jelly-derived Mesenchymal Stem Cells and Magnovision",
      "Phase": "PHASE3",
      "StartDate": "2019-01-01",
      "CompletionDate": "",
      "Status": "COMPLETED",
      "SponsorName": "Ankara Universitesi Teknokent",
      "is_gene_therapy": 0,
      "is_cell_therapy": 1
    },
    {
      "NCTId": "NCT01505062",
      "BriefTitle": "Study of SAR421869 in Participants With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B",
      "Phase": "PHASE1, PHASE2",
      "StartDate": "2012-03-26",
      "CompletionDate": "",
      "Status": "TERMINATED",
      "SponsorName": "Sanofi",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT00447980",
      "BriefTitle": "A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa",
      "Phase": "PHASE2",
      "StartDate": "2007-01-22",
      "CompletionDate": "",
      "Status": "COMPLETED",
      "SponsorName": "Neurotech Pharmaceuticals",
      "is_gene_therapy": 0,
      "is_cell_therapy": 1
    },
    {
      "NCTId": "NCT05748873",
      "BriefTitle": "Promising ROd-cone DYstrophy Gene TherapY",
      "Phase": "PHASE1, PHASE2",
      "StartDate": "2023-04-12",
      "CompletionDate": "2029-03-01",
      "Status": "RECRUITING",
      "SponsorName": "SparingVision",
      "is_gene_therapy": 1,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT05537220",
      "BriefTitle": "Oral N-acetylcysteine for Retinitis Pigmentosa",
      "Phase": "PHASE3",
      "StartDate": "2023-10-11",
      "CompletionDate": "2029-05-01",
      "Status": "ACTIVE_NOT_RECRUITING",
      "SponsorName": "Johns Hopkins University",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT02709876",
      "BriefTitle": "Autologous Bone Marrow-Derived CD34+, CD133+, and CD271+ Stem Cell Transplantation for Retinitis Pigmentosa",
      "Phase": "PHASE1, PHASE2",
      "StartDate": "",
      "CompletionDate": "2021-03-01",
      "Status": "UNKNOWN",
      "SponsorName": "Stem Cells Arabia",
      "is_gene_therapy": 0,
      "is_cell_therapy": 1
    },
    {
      "NCTId": "NCT02804360",
      "BriefTitle": "Intravitreal Dexamethasone Implant in Retinitis Pigmentosa-related Macular Edema- a Retrospective Study",
      "Phase": "PHASE2",
      "StartDate": "",
      "CompletionDate": "2016-12-01",
      "Status": "UNKNOWN",
      "SponsorName": "Rafic Hariri University Hospital",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT04919473",
      "BriefTitle": "Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravitreal vMCO-I in Patients With Advanced Retinitis Pigmentosa",
      "Phase": "PHASE1, PHASE2",
      "StartDate": "2019-10-23",
      "CompletionDate": "",
      "Status": "COMPLETED",
      "SponsorName": "Nanoscope Therapeutics Inc.",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT06787482",
      "BriefTitle": "Evaluating a New Peptide Therapy for Retinal Diseases: AMD, Diabetic Retinopathy, and Dystrophies",
      "Phase": "PHASE1, PHASE2",
      "StartDate": "2024-11-12",
      "CompletionDate": "2025-12-01",
      "Status": "RECRUITING",
      "SponsorName": "Ace Cells Lab Limited",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT06275620",
      "BriefTitle": "A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)",
      "Phase": "PHASE2",
      "StartDate": "2023-11-14",
      "CompletionDate": "2029-12-01",
      "Status": "ENROLLING_BY_INVITATION",
      "SponsorName": "Beacon Therapeutics",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT04278131",
      "BriefTitle": "BS01 in Patients With Retinitis Pigmentosa",
      "Phase": "PHASE1, PHASE2",
      "StartDate": "2020-02-06",
      "CompletionDate": "",
      "Status": "RECRUITING",
      "SponsorName": "Bionic Sight LLC",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT03584165",
      "BriefTitle": "Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa",
      "Phase": "PHASE3",
      "StartDate": "2018-06-04",
      "CompletionDate": "",
      "Status": "ENROLLING_BY_INVITATION",
      "SponsorName": "NightstaRx Ltd, a Biogen Company",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT00063765",
      "BriefTitle": "Evaluation of Safety of Ciliary Neurotrophic Factor Implants in the Eye",
      "Phase": "PHASE1",
      "StartDate": "",
      "CompletionDate": "2006-03-01",
      "Status": "COMPLETED",
      "SponsorName": "National Eye Institute (NEI)",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT06592131",
      "BriefTitle": "BF844 Safety and Pharmacokinetic Study in Healthy Volunteers",
      "Phase": "PHASE1",
      "StartDate": "2024-09-09",
      "CompletionDate": "",
      "Status": "NOT_YET_RECRUITING",
      "SponsorName": "EyeXCel Pty. Ltd.",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT01786395",
      "BriefTitle": "Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis Pigmentosa",
      "Phase": "PHASE3",
      "StartDate": "",
      "CompletionDate": "",
      "Status": "TERMINATED",
      "SponsorName": "R-Tech Ueno, Ltd.",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT01482195",
      "BriefTitle": "Trial of Subretinal Injection of (rAAV2-VMD2-hMERTK)",
      "Phase": "PHASE1",
      "StartDate": "",
      "CompletionDate": "2019-08-01",
      "Status": "COMPLETED",
      "SponsorName": "King Khaled Eye Specialist Hospital",
      "is_gene_therapy": 1,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT03326336",
      "BriefTitle": "Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa",
      "Phase": "PHASE1, PHASE2",
      "StartDate": "2018-09-26",
      "CompletionDate": "2025-12-01",
      "Status": "RECRUITING",
      "SponsorName": "GenSight Biologics",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT03116113",
      "BriefTitle": "A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112",
      "Phase": "PHASE1, PHASE2",
      "StartDate": "2017-03-08",
      "CompletionDate": "",
      "Status": "COMPLETED",
      "SponsorName": "Biogen",
      "is_gene_therapy": 1,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT03490019",
      "BriefTitle": "Treatment of Bardet-Biedl-Syndrome With Metformin for Evaluation of a Possible Visual Improvement",
      "Phase": "PHASE2",
      "StartDate": "2018-04-01",
      "CompletionDate": "2020-08-01",
      "Status": "WITHDRAWN",
      "SponsorName": "University Hospital Tuebingen",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT04850118",
      "BriefTitle": "A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP",
      "Phase": "PHASE2, PHASE3",
      "StartDate": "2024-03-14",
      "CompletionDate": "2029-10-01",
      "Status": "RECRUITING",
      "SponsorName": "Beacon Therapeutics",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT02465749",
      "BriefTitle": "Clinical Trials of Continuous Oxygen Therapy Combined With Blue Light Deprivation in the Treatment of Retinitis Pigmentosa",
      "Phase": "EARLY_PHASE1",
      "StartDate": "",
      "CompletionDate": "2025-06-01",
      "Status": "UNKNOWN",
      "SponsorName": "Sun Yat-sen University",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT06333249",
      "BriefTitle": "A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE)",
      "Phase": "PHASE2",
      "StartDate": "2021-04-13",
      "CompletionDate": "2027-02-01",
      "Status": "ACTIVE_NOT_RECRUITING",
      "SponsorName": "Beacon Therapeutics",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT01543906",
      "BriefTitle": "Oral QLT091001 in Retinitis Pigmentosa (RP) Subjects With an Autosomal Dominant Mutation in Retinal Pigment Epithelial 65 Protein (RPE65)",
      "Phase": "PHASE1",
      "StartDate": "",
      "CompletionDate": "2014-08-01",
      "Status": "COMPLETED",
      "SponsorName": "QLT Inc.",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT04517149",
      "BriefTitle": "4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)",
      "Phase": "PHASE1, PHASE2",
      "StartDate": "2020-06-09",
      "CompletionDate": "2029-05-01",
      "Status": "ACTIVE_NOT_RECRUITING",
      "SponsorName": "4D Molecular Therapeutics",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT00458575",
      "BriefTitle": "A Study to Evaluate the Safety of CNTO 2476 in Patients With Advanced Retinitis Pigmentosa",
      "Phase": "PHASE1",
      "StartDate": "",
      "CompletionDate": "2013-08-01",
      "Status": "TERMINATED",
      "SponsorName": "Centocor, Inc.",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT01736059",
      "BriefTitle": "Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy",
      "Phase": "PHASE1",
      "StartDate": "",
      "CompletionDate": "2025-10-01",
      "Status": "ACTIVE_NOT_RECRUITING",
      "SponsorName": "University of California, Davis",
      "is_gene_therapy": 0,
      "is_cell_therapy": 1
    },
    {
      "NCTId": "NCT05176717",
      "BriefTitle": "Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste)",
      "Phase": "PHASE2, PHASE3",
      "StartDate": "2021-12-15",
      "CompletionDate": "",
      "Status": "TERMINATED",
      "SponsorName": "Laboratoires Thea",
      "is_gene_therapy": 1,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT02739217",
      "BriefTitle": "Safety and Tolerability of PBI-4050 and Its Effects on the Biomarkers in Subjects With Alström Syndrome",
      "Phase": "PHASE2",
      "StartDate": "2016-02-22",
      "CompletionDate": "",
      "Status": "COMPLETED",
      "SponsorName": "Liminal BioSciences Ltd.",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT00345917",
      "BriefTitle": "Safety Study in Retinal Transplantation for Retinitis Pigmentosa.",
      "Phase": "PHASE2",
      "StartDate": "",
      "CompletionDate": "2012-03-01",
      "Status": "COMPLETED",
      "SponsorName": "Radtke, Norman D., M.D.",
      "is_gene_therapy": 0,
      "is_cell_therapy": 1
    },
    {
      "NCTId": "NCT01530659",
      "BriefTitle": "Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa",
      "Phase": "PHASE2",
      "StartDate": "",
      "CompletionDate": "",
      "Status": "COMPLETED",
      "SponsorName": "Neurotech Pharmaceuticals",
      "is_gene_therapy": 0,
      "is_cell_therapy": 1
    },
    {
      "NCTId": "NCT06388200",
      "BriefTitle": "A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa",
      "Phase": "PHASE3",
      "StartDate": "2024-06-18",
      "CompletionDate": "",
      "Status": "RECRUITING",
      "SponsorName": "Ocugen",
      "is_gene_therapy": 1,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT01560715",
      "BriefTitle": "Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa",
      "Phase": "PHASE2",
      "StartDate": "",
      "CompletionDate": "2013-06-01",
      "Status": "COMPLETED",
      "SponsorName": "University of Sao Paulo",
      "is_gene_therapy": 0,
      "is_cell_therapy": 1
    },
    {
      "NCTId": "NCT01399515",
      "BriefTitle": "Efficacy and Safety of Oral Valproic Acid for Retinitis Pigmentosa",
      "Phase": "PHASE2",
      "StartDate": "",
      "CompletionDate": "2015-11-01",
      "Status": "COMPLETED",
      "SponsorName": "Seoul National University Hospital",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT06891885",
      "BriefTitle": "A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older with Retinitis Pigmentosa",
      "Phase": "PHASE1, PHASE2",
      "StartDate": "2025-05-01",
      "CompletionDate": "",
      "Status": "NOT_YET_RECRUITING",
      "SponsorName": "Sumitomo Pharma America, Inc.",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT05805007",
      "BriefTitle": "Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa",
      "Phase": "EARLY_PHASE1",
      "StartDate": "2023-09-12",
      "CompletionDate": "2026-04-01",
      "Status": "RECRUITING",
      "SponsorName": "Peking University Third Hospital",
      "is_gene_therapy": 1,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT03078309",
      "BriefTitle": "The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients",
      "Phase": "EARLY_PHASE1",
      "StartDate": "2018-09-01",
      "CompletionDate": "2021-12-01",
      "Status": "UNKNOWN",
      "SponsorName": "Hadassah Medical Organization",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT04284293",
      "BriefTitle": "CNS10-NPC for the Treatment of RP",
      "Phase": "PHASE1",
      "StartDate": "2021-07-22",
      "CompletionDate": "2025-11-01",
      "Status": "RECRUITING",
      "SponsorName": "Cedars-Sinai Medical Center",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT01521793",
      "BriefTitle": "Repeated Treatments of QLT091001 in Subjects With Leber Congenital Amaurosis or Retinitis Pigmentosa (Extension of Study RET IRD 01)",
      "Phase": "PHASE1",
      "StartDate": "",
      "CompletionDate": "2014-06-01",
      "Status": "COMPLETED",
      "SponsorName": "QLT Inc.",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT02661711",
      "BriefTitle": "Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) Study",
      "Phase": "PHASE2",
      "StartDate": "",
      "CompletionDate": "2017-10-01",
      "Status": "COMPLETED",
      "SponsorName": "Moorfields Eye Hospital NHS Foundation Trust",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT06591793",
      "BriefTitle": "Study of Subretinally Injected AAVB-081 in Patients With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa",
      "Phase": "PHASE1, PHASE2",
      "StartDate": "2024-07-02",
      "CompletionDate": "2029-07-01",
      "Status": "RECRUITING",
      "SponsorName": "AAVantgarde Bio Srl",
      "is_gene_therapy": 1,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT04925687",
      "BriefTitle": "Phase 1 Study of Intravitreal Autologous CD34+ Stem Cell Therapy for Retinitis Pigmentosa",
      "Phase": "PHASE1",
      "StartDate": "2021-06-01",
      "CompletionDate": "",
      "Status": "COMPLETED",
      "SponsorName": "University of California, Davis",
      "is_gene_therapy": 0,
      "is_cell_therapy": 1
    },
    {
      "NCTId": "NCT00346333",
      "BriefTitle": "Clinical Trial of Lutein for Patients With Retinitis Pigmentosa Receiving Vitamin A",
      "Phase": "PHASE3",
      "StartDate": "",
      "CompletionDate": "2008-12-01",
      "Status": "COMPLETED",
      "SponsorName": "National Eye Institute (NEI)",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT03073733",
      "BriefTitle": "Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells in Adults With Retinitis Pigmentosa",
      "Phase": "PHASE2",
      "StartDate": "2017-03-01",
      "CompletionDate": "",
      "Status": "COMPLETED",
      "SponsorName": "jCyte, Inc",
      "is_gene_therapy": 0,
      "is_cell_therapy": 1
    },
    {
      "NCTId": "NCT06912633",
      "BriefTitle": "Safety of a Single, Intravitreal Injection of 8.8M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)",
      "Phase": "PHASE2",
      "StartDate": "",
      "CompletionDate": "2026-09-01",
      "Status": "RECRUITING",
      "SponsorName": "jCyte, Inc",
      "is_gene_therapy": 0,
      "is_cell_therapy": 1
    },
    {
      "NCTId": "NCT04671433",
      "BriefTitle": "Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene",
      "Phase": "PHASE3",
      "StartDate": "2020-12-04",
      "CompletionDate": "",
      "Status": "COMPLETED",
      "SponsorName": "Janssen Research & Development, LLC",
      "is_gene_therapy": 1,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT05203939",
      "BriefTitle": "Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis",
      "Phase": "PHASE1, PHASE2",
      "StartDate": "2022-01-24",
      "CompletionDate": "2027-03-01",
      "Status": "ACTIVE_NOT_RECRUITING",
      "SponsorName": "Ocugen",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT03746522",
      "BriefTitle": "Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity",
      "Phase": "PHASE3",
      "StartDate": "2018-11-23",
      "CompletionDate": "",
      "Status": "COMPLETED",
      "SponsorName": "Rhythm Pharmaceuticals, Inc.",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT03944239",
      "BriefTitle": "Safety and Efficacy of Subretinal Transplantation of Clinical Human Embryonic Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Retinitis Pigmentosa",
      "Phase": "PHASE1",
      "StartDate": "",
      "CompletionDate": "2021-12-01",
      "Status": "UNKNOWN",
      "SponsorName": "Qi Zhou",
      "is_gene_therapy": 0,
      "is_cell_therapy": 1
    },
    {
      "NCTId": "NCT03374657",
      "BriefTitle": "A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis Pigmentosa",
      "Phase": "PHASE1, PHASE2",
      "StartDate": "2018-08-22",
      "CompletionDate": "",
      "Status": "ACTIVE_NOT_RECRUITING",
      "SponsorName": "Novartis Pharmaceuticals",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT06291935",
      "BriefTitle": "Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene",
      "Phase": "PHASE1",
      "StartDate": "2023-09-01",
      "CompletionDate": "2026-04-01",
      "Status": "RECRUITING",
      "SponsorName": "ViGeneron GmbH",
      "is_gene_therapy": 1,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT04315025",
      "BriefTitle": "Safety Issues of Peribulbar Injection of UC-MSC in Patients With Retinitis Pigmentosa",
      "Phase": "PHASE1, PHASE2",
      "StartDate": "2018-10-07",
      "CompletionDate": "",
      "Status": "COMPLETED",
      "SponsorName": "PT. Prodia Stem Cell Indonesia",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT06319872",
      "BriefTitle": "The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration",
      "Phase": "PHASE1",
      "StartDate": "2025-05-19",
      "CompletionDate": "",
      "Status": "NOT_YET_RECRUITING",
      "SponsorName": "University of Rochester",
      "is_gene_therapy": 1,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT05147701",
      "BriefTitle": "Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for NAION",
      "Phase": "PHASE1",
      "StartDate": "2022-02-01",
      "CompletionDate": "2026-01-01",
      "Status": "RECRUITING",
      "SponsorName": "The Foundation for Orthopaedics and Regenerative Medicine",
      "is_gene_therapy": 1,
      "is_cell_therapy": 1
    },
    {
      "NCTId": "NCT00029289",
      "BriefTitle": "Effects of Lutein in Retinitis Pigmentosa",
      "Phase": "PHASE1, PHASE2",
      "StartDate": "",
      "CompletionDate": "2002-10-01",
      "Status": "COMPLETED",
      "SponsorName": "National Center for Complementary and Integrative Health (NCCIH)",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT02018692",
      "BriefTitle": "The Effect of Oral Administration of 9-cis Rich Powder of the Alga Dunaliella Bardawil on Visual Functions in Adolescent Patients With Retinitis Pigmentosa",
      "Phase": "PHASE1, PHASE2",
      "StartDate": "2025-03-01",
      "CompletionDate": "",
      "Status": "NOT_YET_RECRUITING",
      "SponsorName": "Sheba Medical Center",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT06646289",
      "BriefTitle": "A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)",
      "Phase": "PHASE2",
      "StartDate": "2024-10-10",
      "CompletionDate": "",
      "Status": "RECRUITING",
      "SponsorName": "Janssen Research & Development, LLC",
      "is_gene_therapy": 1,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT04355689",
      "BriefTitle": "Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome",
      "Phase": "PHASE1, PHASE2",
      "StartDate": "2020-09-03",
      "CompletionDate": "2025-08-01",
      "Status": "ACTIVE_NOT_RECRUITING",
      "SponsorName": "Nacuity Pharmaceuticals, Inc.",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT06565572",
      "BriefTitle": "Antisense Oligonucleotide Treatment for PCARP Disease Due to Mutation in FLVCR1",
      "Phase": "EARLY_PHASE1",
      "StartDate": "2023-08-23",
      "CompletionDate": "",
      "Status": "ENROLLING_BY_INVITATION",
      "SponsorName": "University of Colorado, Denver",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT04945772",
      "BriefTitle": "Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]",
      "Phase": "PHASE2",
      "StartDate": "2021-07-13",
      "CompletionDate": "",
      "Status": "COMPLETED",
      "SponsorName": "Nanoscope Therapeutics Inc.",
      "is_gene_therapy": 1,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT02837640",
      "BriefTitle": "Studying a Potential Protective Effect of L-Dopa on Retinitis Pigmentosa",
      "Phase": "PHASE2",
      "StartDate": "",
      "CompletionDate": "2021-06-01",
      "Status": "UNKNOWN",
      "SponsorName": "Beirut Eye Specialist Hospital",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT06460844",
      "BriefTitle": "Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)",
      "Phase": "PHASE1",
      "StartDate": "2024-08-27",
      "CompletionDate": "2030-10-01",
      "Status": "RECRUITING",
      "SponsorName": "Ray Therapeutics, Inc.",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT06952842",
      "BriefTitle": "Safety and Efficacy of ZVS203e in the Treatment of Retinitis Pigmentosa Caused by RHO Gene Mutation",
      "Phase": "PHASE1, PHASE2",
      "StartDate": "2025-05-18",
      "CompletionDate": "",
      "Status": "NOT_YET_RECRUITING",
      "SponsorName": "Chigenovo Co., Ltd",
      "is_gene_therapy": 1,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT01014052",
      "BriefTitle": "Safety/Proof of Concept Study of Oral QLT091001 in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) Mutations",
      "Phase": "PHASE1",
      "StartDate": "",
      "CompletionDate": "2012-08-01",
      "Status": "COMPLETED",
      "SponsorName": "QLT Inc.",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT04068207",
      "BriefTitle": "Minocycline Treatment in Retinitis Pigmentosa",
      "Phase": "PHASE2",
      "StartDate": "2019-08-25",
      "CompletionDate": "",
      "Status": "COMPLETED",
      "SponsorName": "Sun Yat-sen University",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT04224207",
      "BriefTitle": "Management of Retinitis Pigmentosa by Mesenchymal Stem Cells by Wharton's Jelly Derived Mesenchymal Stem Cells",
      "Phase": "PHASE3",
      "StartDate": "2019-04-01",
      "CompletionDate": "",
      "Status": "COMPLETED",
      "SponsorName": "Ankara Universitesi Teknokent",
      "is_gene_therapy": 0,
      "is_cell_therapy": 1
    },
    {
      "NCTId": "NCT04604899",
      "BriefTitle": "Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa",
      "Phase": "PHASE2",
      "StartDate": "2020-12-01",
      "CompletionDate": "",
      "Status": "COMPLETED",
      "SponsorName": "jCyte, Inc",
      "is_gene_therapy": 0,
      "is_cell_therapy": 1
    },
    {
      "NCTId": "NCT00999609",
      "BriefTitle": "Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis",
      "Phase": "PHASE3",
      "StartDate": "",
      "CompletionDate": "2030-01-01",
      "Status": "ACTIVE_NOT_RECRUITING",
      "SponsorName": "Spark Therapeutics, Inc.",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT01604356",
      "BriefTitle": "Acupuncture for the Treatment of Vision Loss Due to Retinitis Pigmentosa",
      "Phase": "PHASE1",
      "StartDate": "",
      "CompletionDate": "2013-12-01",
      "Status": "COMPLETED",
      "SponsorName": "Johns Hopkins University",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT01233609",
      "BriefTitle": "Trial of Oral Valproic Acid for Retinitis Pigmentosa",
      "Phase": "PHASE2",
      "StartDate": "",
      "CompletionDate": "2015-12-01",
      "Status": "COMPLETED",
      "SponsorName": "Foundation Fighting Blindness",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT00100230",
      "BriefTitle": "DHA and X-Linked Retinitis Pigmentosa",
      "Phase": "PHASE2",
      "StartDate": "",
      "CompletionDate": "2014-08-01",
      "Status": "COMPLETED",
      "SponsorName": "Retina Foundation of the Southwest",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT04966741",
      "BriefTitle": "Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity",
      "Phase": "PHASE3",
      "StartDate": "2022-03-08",
      "CompletionDate": "",
      "Status": "COMPLETED",
      "SponsorName": "Rhythm Pharmaceuticals, Inc.",
      "is_gene_therapy": 1,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT03963154",
      "BriefTitle": "Interventional Study of Implantation of hESC-derived RPE in Patients With RP Due to Monogenic Mutation",
      "Phase": "PHASE1, PHASE2",
      "StartDate": "2019-08-19",
      "CompletionDate": "",
      "Status": "ACTIVE_NOT_RECRUITING",
      "SponsorName": "Centre d'Etude des Cellules Souches",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT05392751",
      "BriefTitle": "Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa",
      "Phase": "PHASE1, PHASE2",
      "StartDate": "2022-06-02",
      "CompletionDate": "",
      "Status": "TERMINATED",
      "SponsorName": "Endogena Therapeutics, Inc",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT06789445",
      "BriefTitle": "A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)",
      "Phase": "PHASE1, PHASE2",
      "StartDate": "2025-03-10",
      "CompletionDate": "2030-10-01",
      "Status": "RECRUITING",
      "SponsorName": "BlueRock Therapeutics",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT06628947",
      "BriefTitle": "A Phase II Study of Intravitreal KIO-301 in Patients with Late-stage Retinitis Pigmentosa",
      "Phase": "PHASE2",
      "StartDate": "",
      "CompletionDate": "2026-05-01",
      "Status": "NOT_YET_RECRUITING",
      "SponsorName": "Kiora Pharmaceuticals, Inc.",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT04636853",
      "BriefTitle": "CB-PRP in Retinitis Pigmentosa and Dry Age-related Macular Degeneration",
      "Phase": "PHASE3",
      "StartDate": "2020-12-23",
      "CompletionDate": "",
      "Status": "COMPLETED",
      "SponsorName": "Fondazione Policlinico Universitario Agostino Gemelli IRCCS",
      "is_gene_therapy": 1,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT05282953",
      "BriefTitle": "A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients with Retinitis Pigmentosa and Choroideremia (ABACUS)",
      "Phase": "PHASE1, PHASE2",
      "StartDate": "2022-11-10",
      "CompletionDate": "2025-09-01",
      "Status": "RECRUITING",
      "SponsorName": "Kiora Pharmaceuticals, Inc.",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT01068561",
      "BriefTitle": "Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa",
      "Phase": "PHASE1",
      "StartDate": "",
      "CompletionDate": "2010-02-01",
      "Status": "COMPLETED",
      "SponsorName": "University of Sao Paulo",
      "is_gene_therapy": 0,
      "is_cell_therapy": 1
    },
    {
      "NCTId": "NCT00447993",
      "BriefTitle": "A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa",
      "Phase": "PHASE2",
      "StartDate": "2007-01-08",
      "CompletionDate": "",
      "Status": "COMPLETED",
      "SponsorName": "Neurotech Pharmaceuticals",
      "is_gene_therapy": 0,
      "is_cell_therapy": 1
    },
    {
      "NCTId": "NCT02065011",
      "BriefTitle": "A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1B",
      "Phase": "PHASE2",
      "StartDate": "2013-09-12",
      "CompletionDate": "",
      "Status": "ACTIVE_NOT_RECRUITING",
      "SponsorName": "Sanofi",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT05926583",
      "BriefTitle": "A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa",
      "Phase": "PHASE3",
      "StartDate": "2023-09-12",
      "CompletionDate": "",
      "Status": "RECRUITING",
      "SponsorName": "Janssen Pharmaceutical K.K.",
      "is_gene_therapy": 1,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT05909488",
      "BriefTitle": "Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II",
      "Phase": "PHASE2, PHASE3",
      "StartDate": "2023-09-01",
      "CompletionDate": "",
      "Status": "RECRUITING",
      "SponsorName": "PT. Prodia Stem Cell Indonesia",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT04120883",
      "BriefTitle": "Oral Hydroxychloroquine (HCQ) for Retinitis Pigmentosa Caused by P23H- Rhodopsin (RHO)",
      "Phase": "PHASE1, PHASE2",
      "StartDate": "2020-02-25",
      "CompletionDate": "",
      "Status": "TERMINATED",
      "SponsorName": "University of Michigan",
      "is_gene_therapy": 0,
      "is_cell_therapy": 0
    },
    {
      "NCTId": "NCT03566147",
      "BriefTitle": "Treatment of RP and LCA by Primary RPE Transplantation",
      "Phase": "EARLY_PHASE1",
      "StartDate": "2018-08-01",
      "CompletionDate": "",
      "Status": "UNKNOWN",
      "SponsorName": "Eyecure Therapeutics Inc.",
      "is_gene_therapy": 0,
      "is_cell_therapy": 1
    },
    {
      "NCTId": "NCT03252847",
      "BriefTitle": "Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR)",
      "Phase": "PHASE1, PHASE2",
      "StartDate": "2017-07-31",
      "CompletionDate": "",
      "Status": "COMPLETED",
      "SponsorName": "MeiraGTx UK II Ltd",
      "is_gene_therapy": 1,
      "is_cell_therapy": 0
    }
  ]
}